449 related articles for article (PubMed ID: 32811669)
21. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis.
Pozniak AL; Gallant JE; DeJesus E; Arribas JR; Gazzard B; Campo RE; Chen SS; McColl D; Enejosa J; Toole JJ; Cheng AK
J Acquir Immune Defic Syndr; 2006 Dec; 43(5):535-40. PubMed ID: 17057609
[TBL] [Abstract][Full Text] [Related]
22. Efavirenz and Lopinavir Levels in HIV-Infected Women and Their Nursing Infants, in Mali.
Oumar AA; Bagayoko-Maiga K; Bahachimi A; Maiga M; Cere MC; Diarra Z; Chatelut E; Sylla M; Murphy RL; Dao S; Gandia P
J Pharmacol Exp Ther; 2018 Sep; 366(3):479-484. PubMed ID: 29986950
[TBL] [Abstract][Full Text] [Related]
23. Hair concentrations of antiretrovirals predict viral suppression in HIV-infected pregnant and breastfeeding Ugandan women.
Koss CA; Natureeba P; Mwesigwa J; Cohan D; Nzarubara B; Bacchetti P; Horng H; Clark TD; Plenty A; Ruel TD; Achan J; Charlebois ED; Kamya MR; Havlir DV; Gandhi M
AIDS; 2015 Apr; 29(7):825-30. PubMed ID: 25985404
[TBL] [Abstract][Full Text] [Related]
24. Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.
Dahourou DL; Amorissani-Folquet M; Malateste K; Amani-Bosse C; Coulibaly M; Seguin-Devaux C; Toni T; Ouédraogo R; Blanche S; Yonaba C; Eboua F; Lepage P; Avit D; Ouédraogo S; Van de Perre P; N'Gbeche S; Kalmogho A; Salamon R; Meda N; Timité-Konan M; Leroy V;
BMC Med; 2017 Apr; 15(1):85. PubMed ID: 28434406
[TBL] [Abstract][Full Text] [Related]
25. Dosage Optimization of Efavirenz Based on a Population Pharmacokinetic-Pharmacogenetic Model of HIV-infected Patients in Thailand.
Chaivichacharn P; Avihingsanon A; Manosuthi W; Ubolyam S; Tongkobpetch S; Shotelersuk V; Punyawudho B
Clin Ther; 2020 Jul; 42(7):1234-1245. PubMed ID: 32451120
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF).
Nabisere R; Musaazi J; Denti P; Aber F; Lamorde M; Dooley KE; Aarnoutse R; Sloan DJ; Sekaggya-Wiltshire C
Trials; 2020 Feb; 21(1):181. PubMed ID: 32054536
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of a once-daily single-tablet regimen of tenofovir, lamivudine, and efavirenz assessed at 144 weeks among antiretroviral-naïve and experienced HIV-1-infected Thai adults.
Avihingsanon A; Maek-A-Nantawat W; Gatechompol S; Sapsirisavat V; Thiansanguankul W; Sophonphan J; Thammajaruk N; Ubolyam S; Burger DM; Ruxrungtham K
Int J Infect Dis; 2017 Aug; 61():89-96. PubMed ID: 28627427
[TBL] [Abstract][Full Text] [Related]
28. Population Pharmacokinetics Analysis To Inform Efavirenz Dosing Recommendations in Pediatric HIV Patients Aged 3 Months to 3 Years.
Luo M; Chapel S; Sevinsky H; Savant I; Cirincione B; Bertz R; Roy A
Antimicrob Agents Chemother; 2016 Jun; 60(6):3676-86. PubMed ID: 27067333
[TBL] [Abstract][Full Text] [Related]
29. Risks and Benefits of Dolutegravir- and Efavirenz-Based Strategies for South African Women With HIV of Child-Bearing Potential: A Modeling Study.
Dugdale CM; Ciaranello AL; Bekker LG; Stern ME; Myer L; Wood R; Sax PE; Abrams EJ; Freedberg KA; Walensky RP
Ann Intern Med; 2019 May; 170(9):614-625. PubMed ID: 30934067
[TBL] [Abstract][Full Text] [Related]
30. Long-term virological suppression on first-line efavirenz + tenofovir + emtricitabine/lamivudine for HIV-1.
Long-Term Virological Suppression Working Group for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord
AIDS; 2019 Mar; 33(4):745-751. PubMed ID: 30829745
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics of Efavirenz 400 mg Once Daily Coadministered With Isoniazid and Rifampicin in Human Immunodeficiency Virus-Infected Individuals.
Cerrone M; Wang X; Neary M; Weaver C; Fedele S; Day-Weber I; Owen A; Hill A; McClure M; Boffito M
Clin Infect Dis; 2019 Jan; 68(3):446-452. PubMed ID: 30084943
[TBL] [Abstract][Full Text] [Related]
32. Long-Term Effect of Rifampicin-Based Anti-TB Regimen Coadministration on the Pharmacokinetic Parameters of Efavirenz and 8-Hydroxy-Efavirenz in Ethiopian Patients.
Habtewold A; Aklillu E; Makonnen E; Amogne W; Yimer G; Aderaye G; Bertilsson L; Owen JS; Burhenne J
J Clin Pharmacol; 2016 Dec; 56(12):1538-1549. PubMed ID: 27125860
[TBL] [Abstract][Full Text] [Related]
33. Switching safely: pharmacokinetics, efficacy and safety of switching efavirenz to maraviroc twice daily in patients on suppressive antiretroviral therapy.
Waters L; Jackson A; Else L; Rockwood N; Newell S; Back D; Nelson M; Gazzard B; Boffito M
Antivir Ther; 2015; 20(2):157-63. PubMed ID: 24963558
[TBL] [Abstract][Full Text] [Related]
34. Viral load non-suppression status among women exposed to Dolutegravir-based versus Efavirenz-based regimens in Ethiopia: A before-and-after study.
Facha W; Tadesse T; Wolka E; Astatkie A
PLoS One; 2024; 19(6):e0305331. PubMed ID: 38857273
[TBL] [Abstract][Full Text] [Related]
35. Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines.
Phillips AN; Bansi-Matharu L; Venter F; Havlir D; Pozniak A; Kuritzkes DR; Wensing A; Lundgren JD; Pillay D; Mellors J; Cambiano V; Jahn A; Apollo T; Mugurungi O; Ripin D; Da Silva J; Raizes E; Ford N; Siberry GK; Gupta RK; Barnabas R; Revill P; Cohn J; Calmy A; Bertagnolio S
Lancet HIV; 2020 Mar; 7(3):e193-e200. PubMed ID: 32035041
[TBL] [Abstract][Full Text] [Related]
36. Effects of Highly Active Antiretroviral Therapy on Albuminuria in HIVinfected Persons.
Adedeji TA; Adebisi SA; Adedeji NO
Infect Disord Drug Targets; 2020; 20(3):374-384. PubMed ID: 31389318
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics and Drug-Drug Interactions of Isoniazid and Efavirenz in Pregnant Women Living With HIV in High TB Incidence Settings: Importance of Genotyping.
Gausi K; Wiesner L; Norman J; Wallis CL; Onyango-Makumbi C; Chipato T; Haas DW; Browning R; Chakhtoura N; Montepiedra G; Aaron L; McCarthy K; Bradford S; Vhembo T; Stranix-Chibanda L; Masheto GR; Violari A; Mmbaga BT; Aurpibul L; Bhosale R; Nevrekhar N; Rouzier V; Kabugho E; Mutambanengwe M; Chanaiwa V; Nyati M; Mhembere T; Tongprasert F; Hesseling A; Shin K; Zimmer B; Costello D; Jean-Philippe P; Sterling TR; Theron G; Weinberg A; Gupta A; Denti P;
Clin Pharmacol Ther; 2021 Apr; 109(4):1034-1044. PubMed ID: 32909316
[TBL] [Abstract][Full Text] [Related]
38. Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon.
Calmy A; Tovar Sanchez T; Kouanfack C; Mpoudi-Etame M; Leroy S; Perrineau S; Lantche Wandji M; Tetsa Tata D; Omgba Bassega P; Abong Bwenda T; Varloteaux M; Tongo M; Mpoudi-Ngolé E; Montoyo A; Mercier N; LeMoing V; Peeters M; Reynes J; Delaporte E;
Lancet HIV; 2020 Oct; 7(10):e677-e687. PubMed ID: 33010241
[TBL] [Abstract][Full Text] [Related]
39. The Association of Intraocular Efavirenz Concentrations and HIV-1 Viral Load Among Persons With HIV.
Zhang P; Qian Y; Wang L; Suo J; Yin L; Wang Y; Zhang L; Wang Z
J Acquir Immune Defic Syndr; 2024 Jul; 96(3):299-303. PubMed ID: 38534141
[TBL] [Abstract][Full Text] [Related]
40. Randomized clinical trial on efficacy of fixed-dose efavirenz/tenofovir/emtricitabine on alternate days versus continuous treatment.
Bellagamba R; Giancola ML; Tommasi C; Piselli P; Tempestilli M; Angeletti C; Zaccarelli M; Ammassari A; Pinnetti C; Gallo AL; Antinori A; Narciso P; Nicastri E;
AIDS; 2019 Mar; 33(3):493-502. PubMed ID: 30702517
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
